The prescription opioid conundrum: 21st century solutions to a millennia-long problem

References

• Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician. 2017 Feb;20(2S):S3–S92.
   PubMed Web of Science ®Google Scholar
• Tick H, Nielsen A, Pelletier KR, et al. Evidence-based nonpharmacologic strategies for comprehensive pain care: the consortium pain task force white paper. Explore (NY). 2018 Mar;1(14):177–211.
   Google Scholar
• IOM (Institute of Medicine). Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011.
   Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016 Apr 19;315(15):1624–1645.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019 Jun 13;380(24):2285–2287.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Cheville A. Management of chronic pain in the aftermath of the opioid backlash. JAMA. 2017 Jun 20;317(23):2365–2366.
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–847.
   PubMed Web of Science ®Google Scholar
• Hauser W, Bock F, Engeser P, et al. Clinical practice guideline: long-term opioid use in non-cancer pain. Dtsch Arztebl Int. 2014 Oct 24;111(43):732–740.
   PubMedGoogle Scholar
• Shaw E, Braza DW, Cheng DS, et al. American academy of physical medicine and rehabilitation position statement on opioid prescribing. Pm R. 2018 Jun;10(6):681–683.
   PubMedGoogle Scholar
• Moskovitz BL, Benson CJ, Patel AA, et al. Analgesic treatment for moderate-to-severe acute pain in the United States: patients’ perspectives in the physicians partnering against pain (P3) survey. J Opioid Manag. 2011 Jul-Aug;7(4):277–286.
   PubMedGoogle Scholar
• Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014 Dec 20;32(36):4149–4154.
   PubMed Web of Science ®Google Scholar
• Hunnicutt JN, Ulbricht CM, Tjia J, et al. Pain and pharmacologic pain management in long-stay nursing home residents. Pain. 2017 Jun;158(6):1091–1099.
   PubMed Web of Science ®Google Scholar
• Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016 Mar;75(3):552–559.
   PubMed Web of Science ®Google Scholar
• Bennett M, Paice JA, Wallace M. Pain and opioids in cancer care: benefits, risks, and alternatives. Am Soc Clin Oncol Educ Book. 2017;37:705–713.
   PubMedGoogle Scholar
• Giannitrapani KF, Ahluwalia SC, McCaa M, et al. Barriers to using nonpharmacologic approaches and reducing opioid use in primary care. Pain Med. 2017 Oct 20. [ Epub ahead of print]. DOI:10.1093/pm/pnx220.
   PubMed Web of Science ®Google Scholar
• Iwanicki JL, Severtson SG, McDaniel H, et al. Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. PLoS One. 2016;11(12):e0167499.
   PubMed Web of Science ®Google Scholar
• Gudin JA, Laitman A, Nalamachu S. Opioid related endocrinopathy. Pain Med. 2015 Oct;16(Suppl 1):S9–15.
   PubMedGoogle Scholar
• Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017 Oct;30(10):CD012509.
   Google Scholar
• Kissin I. Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety? J Pain Res. 2013;6:513–529.
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane review. Spine (Phila Pa 1976). 2014 Apr 1;39(7):556–563.
   PubMed Web of Science ®Google Scholar
• Tayeb BO, Barreiro AE, Bradshaw YS, et al. Durations of opioid, nonopioid drug, and behavioral clinical trials for chronic pain: adequate or inadequate? Pain Med. 2016 Nov;17(11):2036–2046.
   PubMed Web of Science ®Google Scholar
• Faculty of Pain Medicine of the Royal College of Aneasthetists. The effectiveness of opioids for long term pain. London, UK: The Royal College of Anaesthetists; 2018.
   Google Scholar
• Hauser W, Bernardy K, Maier C. [Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks]. Schmerz. 2015 Feb;29(1):96–108.
   PubMed Web of Science ®Google Scholar
• Arora S, Setnik B, Michael D, et al. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain. J Opioid Manag. 2014 Nov-Dec;10(6):423–436.
   PubMedGoogle Scholar
• Blagden M, Hafer J, Duerr H, et al. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials. Neurogastroenterol Motil. 2014 Dec;26(12):1792–1801.
   PubMed Web of Science ®Google Scholar
• Nalamachu S, Rauck RL, Hale ME, et al. A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain. J Pain Res. 2014;7:669–678.
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015 Mar;23(3):823–830.
   PubMed Web of Science ®Google Scholar
• Bartoli A, Michna E, He E, et al. Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets. J Opioid Manag. 2015 Nov-Dec;11(6):519–533.
   PubMedGoogle Scholar
• Bartoli A, Michna E, He E, et al. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain. Postgrad Med. 2015 Jan;127(1):5–12.
   PubMed Web of Science ®Google Scholar
• Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther. 2015 Nov 1;37(11):2420–2438.
   PubMed Web of Science ®Google Scholar
• Hale ME, Zimmerman TR, Ma Y, et al. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain. J Opioid Manag. 2015 Sep-Oct;11(5):425–434.
   PubMedGoogle Scholar
• Wen W, Taber L, Lynch SY, et al. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain. J Opioid Manag. 2015 Jul-Aug;11(4):339–356.
   PubMedGoogle Scholar
• Guerriero F, Roberto A, Greco MT, et al. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study. Drug Des Devel Ther. 2016;10:1515–1523.
   PubMed Web of Science ®Google Scholar
• Hale ME, Ma Y, Malamut R. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: safety, maintenance of analgesia, and abuse potential. J Opioid Manag. 2016 May-Jun;12(2):139–147.
   PubMedGoogle Scholar
• Taber L, Lynch SY, He E, et al. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain. Postgrad Med. 2016 Jan;128(1):23–33.
   PubMed Web of Science ®Google Scholar
• Broglio K, Pergolizzi J, Kowalski M, et al. Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic pain. Geriatr Nurs. 2017 Jan-Feb;38(1):39–47.
   PubMed Web of Science ®Google Scholar
• Hale M, Urdaneta V, Kirby MT, et al. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–240.
   PubMed Web of Science ®Google Scholar
• Hale ME, Zimmerman TR Jr., Ma Y, et al. Evaluation of quality of life, functioning, disability, and work/school productivity following treatment with an extended-release hydrocodone tablet formulated with abuse-deterrence technology: a 12-month open-label study in patients with chronic pain. Pain Pract. 2017 Feb;17(2):229–238.
   PubMed Web of Science ®Google Scholar
• Taber L, Baldridge S, He E, et al. Hysingla(R) ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis. Postgrad Med. 2017 Jan;129(1):133–139.
   PubMed Web of Science ®Google Scholar
• Dupoiron D, Stachowiak A, Loewenstein O, et al. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. Eur J Pain. 2017 Oct;21(9):1485–1494.
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Kowalski M, He E. Effectiveness and safety of once-daily extended-release hydrocodone in individuals previously receiving immediate-release oxycodone for chronic pain. Pain Med. 2018 May 1;19(5):967–977.
   PubMed Web of Science ®Google Scholar
• Epstein DH, Heilig M, Shaham Y. Science-based actions can help address the opioid crisis. Trends Pharmacol Sci. 2018 Nov;39(11):911–916.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Viscusi ER. The use of opioid analgesics for chronic pain: minimizing the risk for harm. Am J Gastroenterol Suppl. 2014 Sep 10;2(1):3–8.
   PubMedGoogle Scholar
• Hegmann KT, Weiss MS, Bowden K, et al. ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med. 2014 Dec;56(12):e143–59.
   PubMed Web of Science ®Google Scholar
• Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018 Dec 18;320(23):2448–2460.
   PubMed Web of Science ®Google Scholar
• Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018 Mar 6;319(9):872–882.
   PubMed Web of Science ®Google Scholar
• LeResche L, Saunders K, Dublin S, et al. Sex and age differences in global pain status among patients using opioids long term for chronic noncancer pain. J Womens Health (Larchmt). 2015 Aug;24(8):629–635.
   PubMed Web of Science ®Google Scholar
• New Jersey Academy of Family Physicians. New prescribing law for treatment of acute and chronic pain. Trenton, NJ: New Jersey Academy of Family Physicians. [cited 2018 Aug 8]. Available from: https://www.njafp.org/content/new-prescribing-law-treatment-acute-and-chronic-pain
   Google Scholar
• Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017 Dec;6(Suppl 1):35–42.
   PubMed Web of Science ®Google Scholar
• Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: visual analog scale for pain (VAS Pain), Numeric rating scale for pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63(Suppl 11):S240–52.
   PubMed Web of Science ®Google Scholar
• Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016 Sep 20;34(27):3325–3345.
   PubMed Web of Science ®Google Scholar
• Brennan MJ. Update on prescription extended-release opioids and appropriate patient selection. J Multidiscip Healthc. 2013;6:265–280.
   PubMedGoogle Scholar
• Hamburg MA Crafting better drug labeling to ensure safer use of opioids FDA Voice: FDA; 2013 [Updated 2013 Sept 10; cited 2018 Jul 1]. Available from: https://blogs.fda.gov/fdavoice/index.php/2013/09/crafting-better-drug-labeling-to-ensure-safer-use-of-opioids/
   Google Scholar
• Lee YH, Brown DL, Chen HY. Current impact and application of abuse-deterrent opioid formulations in clinical practice. Pain Physician. 2017 Nov;20(7):E1003–E1023.
   PubMed Web of Science ®Google Scholar
• Litman RS, Pagan OH, Cicero TJ. Abuse-deterrent opioid formulations. Anesthesiology. 2018 May;128(5):1015–1026.
   PubMed Web of Science ®Google Scholar
• OxyContin (oxycodone hydrochloride) extended-release tablets [prescribing information]. Stamford, CT: Purdue Pharma L.P.; 2018.
   Google Scholar
• Xtampza ER (oxycodone) extended-release capsules [prescribing information]. Stoughton, MA: Collegium Pharmaceutical, Inc.; 2018.
   Google Scholar
• RoxyBond (oxycodone hydrochloride) tablets [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2018.
   Google Scholar
• Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride) extended-release tablets [prescribing information]. Stamford, CT: Purdue Pharma L.P.; 2016.
   Google Scholar
• Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules [prescribing information]. New York, NY: Pfizer Inc; 2016.
   Google Scholar
• Hysingla ER (hydrocodone bitartrate) extended-release tablets [prescribing information]. Stamford, CT: Purdue Pharma L.P.; 2018.
   Google Scholar
• Vantrela ER (hydrocodone bitartrate) extended-release tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2017.
   Google Scholar
• Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules [prescribing information]. New York, NY: Pfizer Inc; 2018.
   Google Scholar
• MorphaBond ER (morphine sulfate) extended-release tablets [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2018.
   Google Scholar
• Arymo ER (morphine sulfate) extended-release tablets [prescribing information]. Wayne, PA: Egalet US Inc; 2018.
   Google Scholar
• Johnson F, Setnik B. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. Pain Physician. 2011 Jul-Aug;14(4):391–406.
   PubMed Web of Science ®Google Scholar
• Jang DH, Rohe JC, Hoffman RS, et al. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med. 2010 Mar;55(3):303–304.
   PubMed Web of Science ®Google Scholar
• Ruan X, Chen T, Gudin J, et al. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010 Jul-Aug;6(4):300–303.
   PubMedGoogle Scholar
• Apadaz (benzhydrocodone and acetaminophen) tablets [prescribing information]. Coralville, IA: KemPharm, Inc.; 2018.
   Google Scholar
• Michna E, Cheng WY, Korves C, et al. Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management. Pain Med. 2014 Jan;15(1):79–92.
   PubMed Web of Science ®Google Scholar
• Webster LR, Rolleri RL, Pixton GC, et al. Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users. Subst Abuse Rehabil. 2012;3:101–113.
   PubMedGoogle Scholar
• Setnik B, Bramson C, Bass A, et al. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users. J Clin Pharmacol. 2015 Dec;55(12):1351–1361.
   PubMed Web of Science ®Google Scholar
• Webster LR, Kopecky EA, Smith MD, et al. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med. 2016 Jun;17(6):1112–1130.
   PubMed Web of Science ®Google Scholar
• Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). J Clin Pharmacol. 2017 Apr;57(4):500–512.
   PubMed Web of Science ®Google Scholar
• Setnik B, Schoedel K, Bartlett C, et al. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users. J Opioid Manag. 2017 Nov/Dec;13(6):449–464.
   PubMedGoogle Scholar
• Setnik B, Bass A, Bramson C, et al. Abuse potential study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone administered orally to nondependent recreational opioid users. Pain Med. 2017 Jun 1;18(6):1077–1088.
   PubMed Web of Science ®Google Scholar
• Webster LR, Pantaleon C, Shah MS, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine-morphine ARER. Pain Med. 2017 Jul 1;18(7):1303–1313.
   PubMed Web of Science ®Google Scholar
• Webster LR, Smith MD, Lawler J, et al. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (morphine-ADER injection-molded tablets) vs extended-release morphine administered intranasally in nondependent recreational opioid users. Pain Med. 2017 Sep 1;18(9):1695–1705.
   PubMed Web of Science ®Google Scholar
• Webster LR, Iverson M, Pantaleon C, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal human abuse potential study of oxycodone ARIR, a novel, immediate-release, abuse-deterrent formulation. Pain Med. 2019 Mar;28(20):747–757.
   Google Scholar
• Webster LR, Pantaleon C, Iverson M, et al. Intranasal pharmacokinetics of morphine ARER, a novel abuse-deterrent formulation: results from a randomized, double-blind, four-way crossover study in nondependent, opioid-experienced subjects. Pain Res Manag. 2018;2018:7276021.
   PubMed Web of Science ®Google Scholar
• Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1274–1282.
   PubMed Web of Science ®Google Scholar
• Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016 Nov;1(168):219–229.
   Google Scholar
• Wagner A States have stalled on potential opioid abuse solution: deterrent formulation drugs: multiState. 2017. [cited 2018 Jul 7]. Available from: https://www.multistate.us/blog/state-efforts-have-stalled-on-potential-opioid-abuse-solution-deterrent-formulation-drugs
   Google Scholar
• Huskamp HA, Riedel LE, Barry CL, et al. Coverage of medications that treat opioid use disorder and opioids for pain management in marketplace plans, 2017. Med Care. 2018 Jun;56(6):505–509.
   PubMed Web of Science ®Google Scholar